Predictors of Return to Work During 3 Years After Start of First Tumor Necrosis Factor Antagonist in a National Cohort of Biologics-Treated Patients with Rheumatoid Arthritis.

被引：0
|
作者：
Olofsson, Tor [1 ]
Petersson, Ingemar F. [2 ]
Eriksson, Jonas [3 ]
Englund, Martin [2 ]
Geborek, Pierre [1 ]
Jacobsson, Lennart T. H. [4 ]
Askling, Johan [3 ]
Neovius, Martin [3 ]
机构：
[1] Lund Univ, Rheumatol Sect, Dept Clin Sci Lund, Lund, Sweden
[2] Lund Univ, Dept Orthoped, Lund, Sweden
[3] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden
[4] Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
826
引用
收藏
页码：S359 / S360
页数：2
相关论文
共 50 条
  • [21] Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis -: Results from a large UK national cohort study
    Hyrich, Kimme L.
    Lunt, Mark
    Watson, Kath D.
    Symmons, Deborah P. M.
    Silman, Alan J.
    [J]. ARTHRITIS AND RHEUMATISM, 2007, 56 (01): : 13 - 20
  • [22] Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents
    Tanaka, Michi
    Sakai, Ryoko
    Koike, Ryuji
    Harigai, Masayoshi
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (09) : 1726 - 1728
  • [23] Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment?
    Askling, Johan
    van Vollenhoven, Ronald F.
    Granath, Fredrik
    Raaschou, Pauline
    Fored, C. Michael
    Baecklund, Eva
    Dackhammar, Christina
    Feltelius, Nils
    Coster, Lars
    Geborek, Pierre
    Jacobsson, Lennart T.
    Lindblad, Staffan
    Rantapaa-Dahlqvist, Solbritt
    Saxne, Tore
    Klareskog, Lars
    [J]. ARTHRITIS AND RHEUMATISM, 2009, 60 (11): : 3180 - 3189
  • [24] Outpatient Use of Antimicrobials in Patients With Rheumatoid Arthritis Before and After Treatment With Tumor Necrosis Factor Inhibitors: A Nationwide Retrospective Cohort Study
    Bjornsson, Aron H.
    Palsson, Olafur
    Kristjansson, Mar
    Gunnarsson, Petur S.
    Grondal, Gerdur
    Gudbjornsson, Bjorn
    Love, Thorvardur J.
    [J]. ACR OPEN RHEUMATOLOGY, 2022, 4 (02) : 187 - 194
  • [25] Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor
    Conigliaro, Paola
    Chimenti, Maria Sole
    Triggianese, Paola
    Ballanti, Eleonora
    Sunzini, Flavia
    Duca, Iaria
    Perricone, Roberto
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2016, 44 : 90 - 94
  • [26] Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis
    Che, Helene
    Lukas, Cedric
    Morel, Jacques
    Combe, Bernard
    [J]. JOINT BONE SPINE, 2014, 81 (03) : 215 - 221
  • [27] Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study
    Olofsson, Tor
    Englund, Martin
    Saxne, Tore
    Joud, Anna
    Jacobsson, Lennart T. H.
    Geborek, Pierre
    Allaire, Saralynn
    Petersson, Ingemar F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (12) : 2131 - 2136
  • [28] Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors
    Iannone, Florenzo
    Gremese, Elisa
    Atzeni, Fabiola
    Biasi, Domenico
    Botsios, Costantino
    Cipriani, Paola
    Ferri, Clodoveo
    Foschi, Valentina
    Galeazzi, Mauro
    Gerli, Roberto
    Giardina, Annarita
    Marcheson, Antonio
    Salaffi, Fausto
    Ziglioli, Tamara
    Lapadula, Giovanni
    [J]. JOURNAL OF RHEUMATOLOGY, 2012, 39 (06) : 1179 - 1184
  • [29] CASE DEFINITION OF SERIOUS INFECTION AFFECTS INCIDENCE AND PREDICTORS IN AN INCEPTION COHORT OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING ANTI-TUMOR NECROSIS FACTOR THERAPY
    Homik, J.
    Thanh, N.
    Ohinmaa, A.
    Barnabe, C.
    Martin, L.
    Barr, S.
    Maksymowych, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 628 - 629
  • [30] The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database
    Ryoko Sakai
    Soo-Kyung Cho
    Toshihiro Nanki
    Ryuji Koike
    Kaori Watanabe
    Hayato Yamazaki
    Hayato Nagasawa
    Koichi Amano
    Yoshiya Tanaka
    Takayuki Sumida
    Atsushi Ihata
    Shinsuke Yasuda
    Atsuo Nakajima
    Takahiko Sugihara
    Naoto Tamura
    Takao Fujii
    Hiroaki Dobashi
    Yasushi Miura
    Nobuyuki Miyasaka
    Masayoshi Harigai
    [J]. Rheumatology International, 2014, 34 : 1729 - 1736
12345